LONDON and PHILADELPHIA, Sept. 30, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today publishes its unaudited interim results for the six months ended June 30, 2026 (“H1 26”).

H1 highlights and post period

Research & development

Next Generation pre|CISION® pipeline

  • AVA6103 (FAP-Exd)
    • Preliminary preclinical and clinical data with AVA6103 have been presented recently. Data reported in the Phase 1a trial in patients with select solid tumors demonstrate proof of mechanism with two key findings:
      • AVA6103 pre|CISION® controlled-release exatecan demonstrates a clean safety profile through the first three dose levels, including a payload dose level 50% higher than the maximum tolerated dose (MTD) of conventional exatecan at dose level 3, and
      • The comparison of the preclinical modeled pharmacokinetic (PK) data and clinical trial PK data demonstrates an exceptional alignment through the first 3 dose levels with controlled release of exatecan evident in patients for days after dosing
    • The first head-to-head preclinical comparison of AVA6103 and Enhertu®, a marketed antibody drug conjugate (ADC) that targets HER2, demonstrates that AVA6103 shows better antitumor activity vs. Enhertu®, with deep and durable responses delivered by our dose dense regimen that has been applied in the FOCUS-01 trial.
    • Updated preclinical pharmacology and exposure data analyses, highlighting the favorable delivery profile, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026.
    • Comparative analyses of pre|CISION® payload delivery preclinical pharmacokinetics (PK) via AVA6103, compared with now two approved ADCs (Enhertu® and Datroway®), presented at the Company’s Science Day, showing the clear advantages of pre|CISION® over traditional ADCs.
    • U.S. Food and Drug Administration (FDA) granted clearance of the Investigational New Drug (IND) application for AVA6103 in January, 2026 and the first patient was treated in the trial in March, 2026.
  • AVA6207 (Dual Payload)
    • Presented first in vivo efficacy and exposure pharmacology for the pre|CISION® dual payload technology program at AACR 2026.
    • Presented updated in vivo studies of the dual payload delivery system AVA6207 at Science Day.

pre|CISION® platform and First Gen (AVA6000)

  • Reported data validating the pre|CISION® ​PDC platform, with AVA6000 in patients with salivary gland cancer, where robust tumor responses are observed with low expression of fibroblast activation protein (FAP) and the persistence of FAP expression despite tumor response.
  • Published new data demonstrating the favorable delivery profile and advantages of pre|CISION® compared to a marketed antibody drug conjugate (ADC)
  • AVA6000 (Faridoxorubicin, pending partnering)
    • Presented updated Phase 1a/1b data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • At the end of Phase 1 meeting, certain pivotal trial elements and the regulatory path forward with Phase 1b data were agreed with the U.S. Food and Drug Administration (FDA) for potential full regulatory approval.
    • Agreed updates with the FDA to the ongoing Phase 1 trial protocol including the removal of the maximum dosing limit and to allow flexibility in dosing levels to identify the dose for further development.

Financial

Strengthened financial position to support R&D programs:

  • Completed oversubscribed placing and subscription, raising £10 million (March 2026), and raised gross proceeds of approximately £9 million in an equity fundraise (June 2026), from institutional investors and existing shareholders.
  • Today, separately announcing a proposed capital raise to further strengthen the balance sheet
  • Cash and short-term deposit balances at June 30, 2026, of £20.27 million (31 December 2025: £16.9 million million). As of August 31, 2026, cash held was £10.59 million.

Corporate

Strengthened leadership and corporate governance via Board appointments:

  • Richard Hughes as non-executive Chairman (June 2026)
  • Patrick Vink as Deputy Chairman (in July 2026)
  • Mats Blom as Chair of the Audit Committee (in September 2026)

Outlook 2026 and beyond

  • The design of the FOCUS-1 trial of AVA6013 and preclinical updates were presented in Trials in Progress presentations at both the American Association of Cancer Research (AACR) Conference on Pancreatic Cancer, being held on September 25-28, 2026, and the European Society for Medical Oncology (ESMO) Congress, being held on October 23-27, 2026.
  • First efficacy data from the FOCUS-01 trial with AVA6103 is anticipated to be presented in H1 2027 – including data from clinical tumor biopsies which are anticipated to confirm AVA6103 is being retained in a ‘drug reservoir’ in the tumor, based on the preliminary Phase 1 data.
  • The selection of the payloads and data to support clinical candidate selection for the Dual Payload Next Gen Program (AVA6207) will be presented in Q4 2026.
  • Clinical data from the First Gen faridoxorubicin (AVA6000) program will also be presented in Q4 2026 at the ESMO Congress, Oct 23-27, 2026.

Christina Coughlin, CEO of Avacta, commented:

“This has been a transformative first half for Avacta, with compelling clinical validation of our pre|CISION® platform delivering robust and durable tumor responses and demonstrating the clear advantages of our approach over conventional ADCs. The controlled-release mechanism of our Next Gen pipeline with AVA6103 as the lead asset is now working in patients, exactly as modelled, and we are moving towards initial efficacy data in 2027.

“This progress is underpinned by a strong and complementary leadership team. We have further reinforced the expertise and governance at Avacta with several senior appointments in 2026 to management and our Board, who bring the benefit of their scientific, industry, markets and financial acumen to the Company as we advance our proprietary pipeline and explore partnering opportunities to maximize the potential of our pre|CISION® platform.

“Our financing activities have raised approximately £19.0 million in 2026 to date, which together with the anticipated proceeds of our planned capital raise being launched today, will ensure funding is in place to execute on multiple value inflection milestones, including the efficacy data on AVA6103 in H1 2027, as well as payload selection for our dual-payload program AVA6207 later this year.”

Enhertu® (trastuzumab deruxtecan; T-DXd) is a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product). Datroway® (datopotamab deruxtecan-dlnk; Dato-DXd) is a protease cleavable-linker ADC, approved for certain types of breast and lung cancer (a Daiichi Sankyo product).

For further information from Avacta, please contact:

Avacta Group plc
Christina Coughlin, Chief Executive Officer
https://avacta.com/
via Cohesion Bureau
   
Strand Hanson Limited (Nominated Adviser)
James Harris / Chris Raggett / James Dance 
 
www.strandhanson.co.uk
 
Zeus (Broker)
James Hornigold / George Duxberry (Investment Banking)
Dominic King / Alex Bartram (Corporate Broking) 
 
www.zeuscapital.co.uk
Cohesion Bureau
Communications / Media / Investors
Chris Maggos 
 
avacta@cohesionbureau.com
 

About Avacta – https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta’s innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer. 

About FAP-Exd (AVA6103)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

Interim report

Strategic overview

We are making excellent progress in the development of our unique pre|CISION® technology platform, pioneering a novel, differentiated class of pre|CISION®-based medicines to revolutionize drug delivery. 

Our platform technology demonstrates multiple advantages over conventional therapeutics by addressing one of the primary challenges of effective treatment of diseases, specifically the balance between efficacy and safety. pre|CISION®-based medicines are specifically designed to be silent (inert) in the bloodstream and in the tissues, and to only activate once in the tumor.

We are confident in Avacta’s ability to partner preCISION® across a number of modalities and in the management team’s ability to secure the requisite funding to progress the pre|CISION® platform through multiple value driving events.

pre|CISION® – our proprietary technology

The challenge in oncology is that the most effective therapies cause the most toxicity in normal tissues. The ability to deliver the active drug directly to the tumor is the promise of our proprietary pre|CISION® platform. Avacta’s innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

The key aspect of pre|CISION® peptide drug conjugate (PDC) technology is that the conjugated drug (the combination of the oncology drug and our peptide) is inert. It is incapable of entering cells and killing until the peptide is specifically released when it comes into contact with common tumor-associated protein, known as fibroblast activation protein or FAP, in the tumor.

When a pre|CISION® PDC encounters FAP in the tumor, the peptide is cleaved and the active payload is released. The release of the payload from the pre|CISION® compound in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than would be achievable with standard systemic administration. Importantly, the increased toxicities (payload) at the tumor are directly associated with the pre|CISION® medicines. 

Two factors that dictate the antitumor potential of pre|CISION® medicines are (1) the expression of FAP in the tumor to cleave the peptide (the amount of the FAP protein that exists in the tumor) and (2) the inherent susceptibility of the associated tumors to the chemotherapy (chemicals in the drug) that is released.

We believe that pre|CISION® can deliver higher drug levels within tumors which will lead to improved antitumor activity while reducing systemic toxicities. This will dramatically impact the therapeutic index and efficacy of a given anticancer drug. We have observed this with our first clinical program, faridoxorubicin. This program has demonstrated a dramatic reduction in the toxicities associated with conventional doxorubicin and is delivering exciting preliminary efficacy data. 

To further extend the pipeline, Avacta has invented the Next Generation Controlled Release pre|CISION technology that adds a chemical capping group and linker with two key advantages: (1) greater control over the release of the payload in the tumor, allowing optimized pharmacokinetic delivery even with payloads that have challenging PK properties, and (2) implementing the linker technology opens a large number of payloads that can be delivered with Next Gen pre|CISION, permitting a full exploration of the landscape opportunity of pre|CISION with ~90% FAP expression among solid tumors.

Programs

Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer. 

Our first generation asset, Faridoxorubicin (AVA6000) continues in Phase 1b. We anticipate presenting data in October, 2026, at the European Society for Medical Oncology (ESMO) meeting from the cohort of patients with salivary gland cancer. This program is intended to go forward within a partnership and discussions are ongoing regarding such an arrangement.

AVA6207 is our Next Gen Dual Payload program which is on track for the goals, in 2H 2026, of naming of the two payloads that will be included in the molecule and clinical candidate selection. Clinical candidate selection is based on the preclinical pharmacology, chemical properties of the molecule with initial assessment of manufacturing for use in the clinic. These data will be presented in the fourth quarter of 2026.

Outlook

Avacta continues to build our value proposition and our unique world-class scientific and clinical capabilities. Our data are robust and building and industry interest in our innovative platform continues to increase. We are very excited about the next stages of Avacta’s journey with the recent clinical data demonstrating proof of mechanism for AVA6103 in the clinic demonstrating the potential in the Next Gen pre|CISION platform. Our upcoming data catalysts demonstrate the progress made in the programs, including the presentation of the FOCUS-01 trial and updated preclinical work with AVA6103, our updated Farodoxorubicin data being presented in October at ESMO, and the payloads and clinical candidate selection in the Next Gen pre|CISION Dual Payload program in the fourth quarter of 2026.

Financial Review

Revenue
Revenues from continuing operations for the six months ended 30 June 2026 were £0.06 million (H1 2025: £0.06 million; FY 2025: £0.113 million).

Revenues from discontinued operations for the six months ended 30 June 2026 was £nil million (H1 2025: £6.10 million; FY 2025: £6.20 million).

Research costs and selling, general and administrative costs
Research costs relate predominantly to the clinical and pre-clinical development work of the pre|CISION® therapeutics programs as planned increased to £9.69 million (H1 2025: £7.20 million; FY 2025: £18.76 million).

Other costs and charges
Depreciation from continuing operations decreased to £0.56 million (H1 2025: £0.73 million; FY 2025: £1.27 million). Amortization expense remained at £0.01 million (H1 2025: £0.01 million; FY 2025: £0.01 million).

The share of the costs from the AffyXell joint venture was £0.26 million (H1 2025: £0.19 million; FY 2025: £0.45 million). The share of losses reflects the Group’s 21% ownership share of the losses accumulated in the year. The Group investment remained at 21%.

Share-based payment charges were £0.54 million (H1 2025: £0.74 million; FY 2025: £2.13 million).

Operating loss
The Group’s operating loss from continuing operations decreased to £13.91 million (H1 2025: £14.18 million; FY 2025: £29.89 million).

Convertible bond costs
During the period, the Group made interest-only cash repayments of £0.66 million in accordance with the amended bond terms and settled a further £1.20 million of the debt component through an early equity conversion.

The Board continues to consider each settlement event as it arises, taking into account a range of factors including the Company’s cash runway, shareholder dilution and broader business prospects.

The bond agreement contains embedded derivatives in conjunction with an ordinary host debt liability. Accordingly, the convertible bonds are presented in the Consolidated Statement of Financial Position as two separate components: ‘Convertible bond – debt’ and ‘Convertible bond – derivative’. The derivative element is measured at fair value using a Monte Carlo option pricing model.

The derivative element was revalued as at 30 June 2026 to £3.29 million (30 June 2025: £0.27 million; 31 December 2025: £2.79 million). After taking account of the £0.37 million reduction arising from the early conversion, this resulted in a £0.87 million charge recognised in profit or loss in the period (H1 2025: £1.01 million credit; FY 2025: £1.51 million debit).

The debt element of the bond increased to £15.77 million (H1 2025: £18.17 million; 31 December 2025: £13.36 million). The movement primarily reflects a non-cash interest expense of £3.46 million and a £0.82 million loss arising from revisions to expected future cash flows, partially offset by £0.66 million of interest-only cash repayments and an early conversion of £1.20 million. As of 30 September, the outstanding loan balance is £12.00 million.

Loss for the period
The reported loss from continuing operations after taxation was £19.02 million (H1 2025: £16.13 million; FY 2025: £36.26 million).

The basic loss per share from continuing operations was 4.23p (H1 2025: 4.23p; FY 2025: 9.07p).

The basic loss per share from discontinued operations was nil (H1 2025: 3.82p; FY 2025: 0.59p).

Cash flow
The Group reported cash and cash-equivalent balances of £20.27 million (30 June 2025: £12.65 million; 31 December 2025: £16.86 million). Cash and cash-equivalents were £10.59 million as of 31 August 2026.

There was a cash outflow from operations and working capital movements of £15.69 million (H1 2025: £12.33 million; FY 2025: £24.93 million) and cash outflow from investing activities was £0.02 million (H1 2025: inflow of £8.77 million; FY 2025: inflow of £9.90 million, reflecting the proceeds of the sale of Launch and Coris).

Cash inflow from financing activities, being net proceeds from the issue of share capital and share options, net of the principal elements of lease payments amounted to £17.76 million (H1 2025: inflow of £0.67 million; FY 2025: inflow of £15.64 million). The cash inflows for H1 2026 and FY 2025 related to equity fundraising.

Financial position

Net assets as at 30 June 2026 were £3.77 million (30 June 2025: £0.14 million; 31 December 2025: £2.48 million) of which cash and cash equivalents amounted to £20.27 million (30 June 2025: £12.65 million; 31 December 2025: £16.86 million).

Right-of-use assets amounting to £0.63 million (30 June 2025: £1.77 million; 31 December 2025: £1.32 million) are recognized in relation to the Group’s leasehold properties, together with a corresponding lease liability of £0.80 million (30 June 2025: £1.97 million; 31 December 2025: £1.55 million).

Intangible assets decreased to £1.55 million (30 June 2025: £1.83 million; 31 December 2025: £1.55 million) due to amortization of intangible assets.

Liabilities in relation to the unsecured senior convertible bonds issued in October 2022 result in a fair value of the derivative element of £3.29 million (30 June 2025: £0.27 million; 31 December 2025: £2.79 million). The convertible bond debt element at 30 June 2026 was £15.77 million (30 June 2025: £18.17 million; 31 December 2025: £13.36 million).

With current committed expenses, current cash runway takes the Group into early first quarter of 2027.

Events after the reporting period

In July 2026 the Company received an accelerated payment notice from the convertible bond holder in respect of the January 2026 quarterly deferred convertible bond repayment, as referenced most recently in the financing announced on 5 June 2026, which the Company has elected to settle in cash. Accordingly, the Company has settled the accelerated quarterly amortization payment of £3.67 million representing principal of £2.4 million together with the associated interest and fees payable in the deferment.

In September 2026 the Company received an accelerated payment notice from the convertible bond holder in respect of the April 2026 quarterly deferred convertible bond repayment, which the Company elected to settle in cash. Accordingly, the Company has settled the accelerated quarterly amortization payment of £2.613 million, representing principal of £2.4 million together with the associated interest and fees payable in the deferment. Following the cash settlement of the April 2026 quarterly deferred convertible bond repayment, both deferred payments have now been satisfied.

As announced on 1 September 2026, the Board of Directors granted share options under the Company’s Equity Share Option Scheme incentive plan (“ESOS”) to all members of the Management Team (the “Options”). The Options are exercisable at an exercise price of 69 pence per share, being the mid-market closing price of the Company’s Ordinary Shares on 27 August 2026, the last trading date before the Options were granted.

As announced on 14 September 2026, Mats Blom, an experienced biotechnology finance executive and Board member with a strong track record as Chief Financial Officer in several life sciences companies, was appointed as a member of its Board of Directors and Chair of the Audit Committee. 

 
Condensed Consolidated Statement of Profit or Loss
for the 6 months ended 30 June 2026
 
    Unaudited     Unaudited     Audited  
 

 Notes 6 months ended
30 June 2026
    6 months ended
30 June 2025
    Year ended
31 December 2025
 
    £000     £000     £000  
                 
Revenue 4 56     56     113  
Cost of sales   –     –     –  
Gross profit   56     56     113  
             
Research costs   (9,686 )   (7,200 )   (18,761 )
R&D expenditure credit (RDEC)   926     –     1,852  
Selling, general and administrative expenses   (3,873 )   (4,470 )   (8,485 )
Adjusted EBITDA   (12,577 )   (11,614 )   (25,281
 
)
Exceptional expenses   23     (899 )   (754 )
Amortization expense   (5 )   (10 )   (11 )
Share of loss of associate   (259 )   (189 )   (454 )
Depreciation expense   (557 )   (728 )   (1,268 )
Share-based payment charge   (536 )   (740 )   (2,126 )
Operating loss   (13,911 )   (14,180 )   (29,894 )
             
Convertible bond – interest expense 6 (3,460 )   (3,865 )   (6,980 )
Convertible bond – revaluation of derivative 6 (869 )   1,009     (1,507 )
Gain/(loss) on modification of financial liabilities 6 (816 )   –     2,031  
Finance income   236     217     371  
Finance costs   (28 )   (53 )   (69 )
 
Loss before tax
   
(18,848
)    
(16,872
)    
(36,048
)
Taxation   (175 )   738     (216 )
Loss from continuing operations   (19,023 )   (16,134 )   (36,264 )
Discontinued operation            
Loss on disposal of subsidiary   –     (705 )   (236 )
Loss from discontinued operation, net of tax   –     (889 )   (2,112 )
Loss for the period   (19,023 )   (17,728 )   (38,612 )
             
Other comprehensive income:            
Foreign currency translation differences   (33 )   711     315  
             
Total comprehensive loss for the period   (19,056 )   (17,017 )   (38,297 )
             
             
Loss per share:            
Basic and diluted   (4.23p )   (4.65p )   (9.66p )

 
Condensed Consolidated Statement of Financial Position
as at 30 June 2026
 
    Unaudited as at     Unaudited as at     Audited as at  
    30 June 2026     30 June 2025     31 December 2025  
    £000     £000     £000  
Assets                  
                   
Property, plant and equipment   187     335     251  
Right-of-use assets   631     1,765     1,319  
Investment in associate   2,901     3,312     3,104  
Intangible assets   1,550     1,834      1,548  
Non-current assets   5,269     7,246     6,222  
             
Trade and other receivables   5,401     3,006     4,479  
Income tax receivable   –     2,400     1,861  
Cash and cash equivalents   20,271     12,645     16,855  
    25,672     18,051     23,195  
Assets directly associated with the assets held for sale   –     3,940     –  
Current assets   25,672     21,991     23,195  
             
Total assets   30,941     29,237     29,417  
             
Liabilities            
             
Lease liabilities   –     (987 )   (496 )
Provisions   (38 )   (208 )   (288 )
             
Non-current liabilities   (38 )   (1,195 )   (784 )
             
Trade and other payables   (7,272 )   (6,600 )   (8,948 )
Lease liabilities   (800 )   (978 )   (1,059 )
Convertible bond – debt 6 (15,774 )   (18,165 )   (13,362 )
Convertible bond – derivative 6 (3,288 )   (273 )   (2,788 )
    (27,134 )   (26,016 )   (26,157 )
Liabilities directly associated with the assets held for sale   –     (1,882 )   –  
Current liabilities   (27,134 )   (27,898 )   (26,157 )
             
Total liabilities   (27,172 )   (29,093 )   (26,941 )
             
Net assets   3,769     144     2,476  
Equity attributable to equity holders of the Company            
Share capital 7 47,240     39,446     44,119  
Share premium   154,063     120,297     137,371  
Reserves   (3,760 )   (1,506 )   (3,727 )
Retained earnings   (193,774 )   (158,093 )   (175,287 )
Total equity   3,769     144     2,476  

Total equity is wholly attributable to equity holders of the parent Company.

Approved by the Board and authorized for issue on 29 September 2026.

 
Condensed Consolidated Statement of Changes in Equity
for the 6 months ended 30 June 2026
 
  Unaudited Unaudited Unaudited   Unaudited   Unaudited   Unaudited   Unaudited  
  Share
Capital
Share
premium
Other
reserve
  Translation
reserve
  Reserve for
own shares
  Retained
earnings
  Total
Equity
 
  £000 £000 £000   £000   £000   £000   £000  
At 1 January 2025 37,018  115,585 (1,729  ) (391 ) (2,373  ) (138,829 ) 9,281  
               
Loss for the period – – –    
–
  –   (17,728 ) (17,728 )
Other comprehensive income for the period – – –   711   –   –   711  
Total comprehensive loss for the period – – –   711   –   (17,728 ) (17,017 )
               
Transactions with owners of the company:        
Exercise of options 823 120 –    –   –    –    943  
Transfer of own shares – – –   –   2,276   (2,276 ) –  
Convertible bond – issue of shares 1,605 4,592 –   –   –   –   6,197  
Equity-settled share based payment –  –  –    –   –    740    740  
               
At 30 June 2025 39,446 120,297 (1,729 ) 320   (97 ) (158,093 ) 144  

Loss for the period – – –    
–
  –   (20,734 ) (20,734 )
Other comprehensive income for the period – – –    
(132
) –   –   (132 )
Total comprehensive loss for the period – – –   (132 ) –   (20,734 ) (20,866 )
               
Transactions with owners of the company:              
Issue of shares 4,273 16,993 –   –   –   –   21,266  
Exercise of options 400 81 –   –   –   –   481  
Transfer of own shares – – –   –   (2,089 ) 2,089   –  
Equity-settled share based payment – – –   –   –   1,451   1,451  
               
At 31 December 2025 44,119 137,371 (1,729 )  
188
  (2,186 ) (175,287 ) 2,476  
               
Loss for the period – – –    
–
  –   (19,023 ) (19,023 )
Other comprehensive income for the period – – –    
(33
) –   –   (33 )
Total comprehensive loss for the period – – –   (33 ) –   (19,023 ) (19,056 )
               
Transactions with owners of the company:              
Issue of shares 2,865 15,154 –   –   –   –   18,019  
Exercise of options 96 130 –   –   –   –   226  
Transfer of own shares – – –   –       –  
Convertible bond – issue of shares 160 1,408 –   –   –   –   1,568  
Equity-settled share based payment – – –   –   –   536   536  
At 30 June 2026 47,240 154,063 (1,729 ) 155   (2,186 ) (193,774 ) 3,769  

             
Condensed Consolidated Statement of Cash Flows
for the 6 months ended 30 June 2026
             
    Unaudited     Unaudited     Audited  
  Note
6 months ended
30 June 2026
    6 months ended
30 June 2025
    Year ended
31 December
2025
 
    £000     £000     £000  
                   
Operating cash outflow from continuing operations 8 (15,689 )   (12,331 )   (24,927 )
             
Interest (paid)/received   (428 )   204     370  
Interest elements of lease payments   (28 )   (54 )   (103 )
Income tax received   1,861     784     784  
Net cash used in continuing operating activities   (14,284 )   (11,397 )   (23,876 )
Net cash from/(used in) discontinued operating activities   –     (2,189 )   (2,906 )
Net cash used in operating activities   (14,284 )   (13,586 )   (26,782 )
             
Cash flows from investing activities            
Purchase of plant and equipment   (16 )   (43 )   (53 )
Sale of subsidiary, net of cash disposed of   –     9,517     9,984  
Purchase of intangible assets   (7 )   –     –  
Net cash used in continuing investing activities   (23 )   9,474     9,931  
Net cash from/(used in) discontinued investing activities   –     (701 )   (31 )
Net cash used in investing activities   (23 )   8,773     9,900  
             
Cash flows from financing activities            
Proceeds from exercise of share options   226     944     1,424  
Cash repayment of convertible bonds   –     –     (5,100 )
Principal elements of lease payments   (489 )   (472 )   (1,001 )
Proceeds from issue of share capital   18,950     –     22,500  
Transaction costs relating to the issue of share capital   (931 )   –     (1,234 )
Net cash used in continuing financing activities   17,756     472     16,589  
Net cash from/(used in) discontinued financing activities   –     194     (946 )
Net cash flow from financing activities   17,756     666     15,643  
     
 
   
 
   
Net increase/(decrease) in cash and cash equivalents   3,449     (4,147 )   (1,239 )
Cash and cash equivalents at the beginning of the period   16,855     17,778     17,778  
Effect of movements in exchange rates on cash held   (33 )   78     316  
             
Cash and cash equivalents at the end of period, including held in disposal group   20,271     13,709     16,855  
Cash held by disposal group   –     (1,064 )   –  
Cash and cash equivalents at end of year   20,271     12,645     16,855  


Notes to the unaudited condensed consolidated financial statements

for the 6 months ended 30 June 2026

1)   Basis of preparation

Avacta Group plc (‘the Company’) is a company incorporated in England and Wales under the Companies Act 2006. These condensed consolidated interim financial statements as at and for the 6 months ended 30 June 2026 (“interim financial statements”) comprise the Company and its subsidiaries (together referred to as ‘the Group’).

The interim financial statements for the 6 months ended 30 June 2026 are unaudited. This information does not constitute statutory accounts as defined in Section 435 of the Companies Act 2006. The financial figures for the year ended 31 December 2025, as set out in this report, do not constitute statutory accounts but are derived from the statutory accounts for that financial year. The statutory accounts for the year ended 31 December 2025 were prepared under IFRS and have been delivered to the Registrar of Companies. The auditors reported on those accounts. Their report was unqualified, did not draw attention to any matters by way of emphasis and did not include a statement under Section 498 of the Companies Act 2006.

The Board confirms that, to the best of its knowledge, these condensed financial statements have been prepared in accordance with IAS34 Interim Financial Reporting and should be read in conjunction with the Group’s last annual consolidated financial statements as at and for the year ended 31 December 2025 (‘last annual financial statements’). They do not include all of the financial information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance since the last annual financial statements.

The Group’s operations and results are not impacted by seasonal fluctuations.

The Board approved these interim financial statements for issue on 29 September 2026.

Going concern

The Financial Statements have been prepared on a going concern basis. The Company’s going concern assessment has been performed as part of the Group’s going concern assessment. 

During the six months ended 30 June 2026, the Group reported a loss from continuing operations of £19.0 million and incurred net cash used in operating activities of £15.7 million.

As at 30 June 2026, cash and cash equivalents were £20.3 million. The Group has external borrowings in the form of a convertible bond, with a principal amount outstanding of £19.2 million as at 30 June 2026.

During the six months ended 30 June 2026, the Group completed equity placings and subscriptions raising gross proceeds of £19.0 million. During the period, the Group also made an interest-only cash repayment of £0.7 million in respect of the convertible bond and a partial conversion resulted in the derecognition of £1.2 million of the host debt liability. 

The Group continues to advance its clinical trials and generate successful data and expects to report further findings in late 2026 and early 2027. Following the data, the Group will evaluate partnering and out-licensing opportunities. 

The Group faces significant risks associated with successful execution of its strategy. These risks include, but are not limited to technology and product development, introduction and market acceptance of new products and services, changes in the marketplace, liquidity, competition from existing and new competitors which may enter the marketplace and retention of key personnel. As a clinical stage oncology business, the Directors anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, growth plans and further development of our technology.

The Directors have considered detailed cash flow forecasts that extended to 31 December 2027, which is at least twelve months from the date of approval of these financial statements (“the going concern period”). The forecasts indicate that we currently have enough cash to fund our planned operations into early first quarter of 2027. The forecasts consider current and future economic conditions that are expected to prevail over the period. These forecasts include assumptions regarding the timing and quantum of investment in the therapeutic development programs together with various scenarios which reflect growth plans, opportunities, risks and mitigating actions. The Board is focused on both the short-term and long-term financing strategy to achieve the company goals including obtaining additional funding through the capital markets.

The forecast therefore shows the Group and the Parent Company are dependent on raising funds to advance their key projects and investments to remain cash positive during the going concern period. There are currently no agreements in place and there is no certainty that funds will be raised within the appropriate timeframe. This indicates that a material uncertainty exists that may cast significant doubt on the Group and the Parent Company’s ability to continue as a going concern, and therefore they may be unable to realise their assets and discharge their liabilities in the normal course of business.

However, the directors have a reasonable expectation that the required funding will be forthcoming. As a result, the directors believe that the Group and the Company will continue as a going concern for a period of at least 12 months from the date of approval of these financial statements and have therefore prepared the financial statements on a going concern basis.

The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate.

2)   Use of judgements and estimates and significant accounting policies

The preparation of the interim financial statements requires management to make judgements and estimates that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognised prospectively.

The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty are consistent with those disclosed in the Group’s annual financial statements for the year ended 31 December 2025.

The accounting policies applied in these interim financial statements are consistent with those applied in the Group’s consolidated financial statements for the year ended 31 December 2025. A number of new standards and amendments became effective from 1 January 2026 but have not had a material impact on the Group’s financial statements.

3)  Segmental reporting

Operating segments – continuing operations

In the view of the Board of Directors, the Group has one (2025: one) reportable segment in continuing operations: Therapeutics. Segment reporting has been presented on this basis for continuing operations. The Directors recognise that the operations of the Group are dynamic and therefore this position will be monitored as the Group develops.

The principal activity of Therapeutics is the development of novel cancer therapies harnessing proprietary technology.

The previous second reportable segment as the diagnostics division which is currently under a divestment strategy and being held for sale. All reporting for this segment will be presented as discontinuing operations.

Segment revenue represents revenue from external customers arising from sale of goods and services, plus inter-segment revenues. Inter-segment transactions are priced on an arm’s length basis. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

The Group’s revenue to destinations outside the UK amounted to 100% (2024: 100%) of total revenue. The revenue analysis below is based on the country of registration of the customer:

    6 months
ended 30
June 2026
  6 months
ended 30
June 2025
  Year ended 31
December 2025
£000            
South Korea   56   56   113
    56   56   113

During the six month period ended 30 June 2026, there were no transactions with a single external customer that exceeded 10% of the Group’s revenue, being £56,000.

During the six month period ended 30 June 2025, there were no transactions with a single external customer that exceeded 10% of the Group’s revenue, being £56,000.

During the year 31 December 2025, transactions with one external customer in the Therapeutics segment amounted individually to 10% or more of the Group’s revenues from continuing operations, being £113,000.

               
Operating segment analysis for the six months ended 30 June 2026
               
 
 
Therapeutics     Central
overheads1
    Total
(continuing)
    Diagnostics
(discontinued)
  £000     £000     £000     £000
Revenue 56     –     56     –
Cost of goods sold –     –     –     –
               
Gross profit 56     –     56     –
                     
Research costs (9,686 )   –     (9,686 )   –
R&D expenditure credit (RDEC) 926     –     926     –
Selling, general and administrative expenses (1,932 )   (1,941 )   (3,873 )   –

Adjusted EBITDA
(10,636 )   (1,941 )   (12,577 )   –
Exceptional expenses –     23     23     –
Depreciation expense (543 )   (14 )   (557 )   –
Amortization expense (2 )   (3 )   (5 )   –
Share of loss of associate (259 )   –     (259 )   –
Share-based payment expense (321 )   (215 )   (536 )   –
               
Segment operating loss (11,761 )   (2,150 )   (13,911 )   –
               

1Central overheads, which relate to operations of the Group functions, are not allocated to the operating segments.

Operating profit/loss is the measure of profit or loss regularly reviewed by the Board. Other items comprising the Group’s loss before tax are not monitored on a segmental basis.

The information reported to the Board does not include balance sheet information at the segment level.

                       
Operating segment analysis for the six months ended 30 June 2025
 
                       
 
 
Therapeutics     Central overheads1     Total
(continuing)
    Diagnostics
(discontinued)
 
  £000     £000     £000     £000  
Revenue 56     –     56     6,102  
Cost of goods sold –     –     –     (3,285 )
               
Gross profit 56     –     56     2,817  
                       
Research costs (7,200 )   –     (7,200 )   –  
Selling, general and administrative expenses (1,493 )   (2,977 )   (4,470 )   (3,465 )
 
Adjusted EBITDA
 
(8,637 )   (2,977 )   (11,614 )   (648 )
Exceptional expenses –     (899 )   (899 )   –  
Depreciation expense (609 )   (119 )   (728 )   (233 )
Amortization expense (3 )   (7 )   (10 )   (31 )
Share of loss of associate (189 )   –     (189 )   –  
Share-based payment expense (365 )   (375 )   (740 )   –  
               
Segment operating loss (9,803 )   (4,377 )   (14,180 )   (912 )
               

1Central overheads, which relate to operations of the Group functions, are not allocated to the operating segments.

Operating profit/loss is the measure of profit or loss regularly reviewed by the Board. Other items comprising the Group’s loss before tax are not monitored on a segmental basis.

The information reported to the Board does not include balance sheet information at the segment level.

                       
Operating segment analysis for the year ended 31 December 2025
 
                       
 
 
Therapeutics     Central
overheads1
    Total
(continuing)
    Diagnostics
(discontinued)
 
  £000     £000     £000     £000  
Revenue 113     –     113     6,199  
Cost of goods sold –     –     –     (3,272 )
               
Gross profit  113     –     113     2,927  
                       
Research costs (18,761 )   –     (18,761 )   –  
R&D expenditure credit (RDEC) 1,852     –     1,852     –  
Selling, general and administrative expenses (4,378 )   (4,106 )   (8,485 )   (4,804 )
 
Adjusted EBITDA
 
(21,174 )   (4,106 )   (25,281 )   (1,877 )
Exceptional expenses –     (754 )   (754 )   –  
Depreciation expense (1,121 )   (147 )   (1,268 )   –  
Amortization expense (6 )   (5 )   (11 )   –  
Share of loss of associate (454 )   –     (454 )   –  
Share-based payment expense (827 )   (1,299 )   (2,126 )   (65 )
               
Segment operating loss (23,582 )   (6,312 )   (29,894 )   (1,942 )
               

1Central overheads, which relate to operations of the Group functions, are not allocated to the operating segments.

Operating profit/loss is the measure of profit or loss regularly reviewed by the Board. Other items comprising the Group’s loss before tax are not monitored on a segmental basis.

The information reported to the Board does not include balance sheet information at the segment level.

4)   Revenue

The Group’s operations and main revenue streams are those described in the last annual financial statements. The Group’s revenue is all derived from contracts with customers.

Disaggregation of revenue

In the following table, revenue is disaggregated by its nature. The table also includes a reconciliation of the disaggregated revenue with the Group’s reportable segments (see Note 3).

Six months ended 30 June 2026

£’000 Therapeutics Continuing
operations
Diagnostics
(discontinued)
Total
Nature of revenue        
Sale of goods – – – –
Provision of services – – – –
Licence-related income 56 56 – 56
  56 56 – 56


Six months ended 30 June 2025

£’000 Therapeutics Continuing
operations
Diagnostics
(discontinued)
Total
Nature of revenue        
Sale of goods – – 5,807 5,807
Provision of services – – 294 294
Licence-related income 56 56 – 56
  56 56 6,102 6,158


Year ended 31 December 2025

£’000 Therapeutics Continuing
operations
Diagnostics
(discontinued)
Total
Nature of revenue        
Sale of goods – – 5,922 5,922
Provision of services – – 277 277
License-related income 113 113 – 113
  113 113 6,199 6,312


5)   Earnings per share

Total Earnings Per Shares Unaudited     Unaudited     Audited  
£’000 6 months ended 30 June 2026     6 months ended 30 June 2025     Year ended 31 December 2025  
               
Loss for the period (19,023 )   (17,728 )   (38,612 )
           
           
Weighted average number of shares (number) 449,438,000     381,243,598     399,784,000  
           
           
Basic and diluted loss per ordinary share (4.23 )   (4.65 )   (9.66 )
           

Continuing Earnings Per Share Unaudited     Unaudited     Audited  
£’000 6 months ended 30 June 2026     6 months ended 30 June 2025     Year ended 31 December 2025  
                 
Loss for the period (19,023 )   (16,134 )   (36,264 )
           
           
Basic and diluted loss per ordinary share (4.23 )   (4.23 )   (9.07 )

Discontinued Earnings Per Share Unaudited     Unaudited     Audited  
£’000 6 months ended 30 June 2026     6 months ended 30 June 2025     Year ended 31 December 2025  
                 
Loss for the period –     (1,594 )   (2,348 )
             
             
Basic and diluted loss per ordinary share –     (3.82 )   (0.59 )


6) Convertible bond

In October 2022, the Group issued senior unsecured convertible bonds (the “Bonds”) with a principal value of £55.0 million to a fund advised by Heights Capital Ireland LLC. The Bonds were issued at 95% of par, generating net proceeds of £52.25 million after placement fees, and bear interest at a fixed coupon of 6.5% per annum, payable quarterly in arrears.

The Bonds have a maturity of five years and include conversion and settlement features that allow repayment in either cash or ordinary shares of Avacta Group plc, at the Group’s option, subject to the contractual terms of the instrument. The Bonds also contain conversion rights permitting the bondholder to convert all or part of the outstanding balance at specified times during the term.

The convertible bond is accounted for as a hybrid financial instrument comprising a host debt liability and an embedded derivative representing the equity-linked conversion and settlement features. The host debt liability is measured at amortised cost while the embedded derivative is measured at fair value through profit or loss. The embedded derivative is valued using a Monte Carlo option pricing model and is classified as a Level 3 fair value measurement under the IFRS fair value hierarchy.

On 20 October 2025, amendments to the terms of the Bonds became effective. The amendments were assessed under IFRS 9 and determined to represent a substantial modification of the liability. Accordingly, the original host debt liability was derecognised and a new host debt liability was recognised at fair value. The embedded derivative remained bifurcated from the host debt liability and continues to be measured separately at fair value through profit or loss.

During the six months ended 30 June 2026, the Group made an interest-only repayment of £0.66 million in cash. In addition, a partial conversion of the Bonds resulted in the derecognition of £1.20 million of host debt liability and £0.37 million of derivative liability, with the corresponding amounts recognised within share capital and share premium. During the period, the carrying amount of the host debt liability was adjusted to reflect revisions to expected future cash flows arising from changes to the repayment profile, including the acceleration of a previously deferred repayment into July 2026. This resulted in a charge of £0.82 million, which has been recognised within Gain/(loss) on modification of financial liabilities in the Consolidated Statement of Profit or Loss.

At 30 June 2026, the carrying amount of the host debt liability was £15.77 million (30 June 2025: £18.17 million; 31 December 2025: £13.36 million) and the carrying amount of the derivative liability was £3.29 million (30 June 2025: £0.27 million; 31 December 2025: £2.79 million). Interest expense recognised in respect of the host debt liability during the period amounted to £3.46 million (H1 2025: £3.87 million; FY 2025: £6.98 million). The remeasurement of the derivative liability resulted in a £0.87 million loss recognised in profit or loss during the period (H1 2025: £1.01 million gain; FY 2025: £1.51 million loss).

Events during the six months ended 30 June 2026

  • On 13 May 2026, a partial conversion of the Bonds resulted in the settlement of £1.20 million of the host debt liability through the issue of ordinary shares. The associated derivative liability of £0.37 million was also derecognised and recognised within equity.

Events following the six months ended 30 June 2026

  • In July 2026 the Company received an accelerated payment notice from the convertible bond holder in respect of the January 2026 quarterly deferred convertible bond repayment, as referenced most recently in the financing announced on 5 June 2026, which the Company has elected to settle in cash. Accordingly, the Company has settled the accelerated quarterly amortization payment of £3.67 million representing principal of £2.4 million together with the associated interest and fees payable in the deferment.
  • In September 2026 the Company received an accelerated payment notice from the convertible bond holder in respect of the April 2026 quarterly deferred convertible bond repayment, which the Company has elected to settle in cash. Accordingly, the Company has settled the accelerated quarterly amortization payment of £2.613 million, representing principal of £2.4 million together with the associated interest and fees payable in the deferment. Following the cash settlement of the April 2026 quarterly deferred convertible bond repayment, both deferred payments have now been satisfied.
  Convertible bond – derivative     Convertible bond –
debt
 
  £000     £000  
At 1 January 2025 1,281     20,497  
Repayments (equity settled) –     (6,197 )
Interest expense –     3,865  
Revaluation of derivative (1,008 )   –  
       
At 30 June 2025 273     18,165  
Derecognition of old financial liability –     (17,289 )
Recognition of new modified liability –     15,258  
Repayments (cash settled) –     (5,887 )
Interest expense –     3,115  
Revaluation of derivative 2,515     –  
       
At 31 December 2025 2,788     13,362  
Repayments interest only (cash settled) –     (663 )
Early conversion (equity settled) (369 )   (1,200 )
Revision to expected cash flows –     816  
Interest expense –     3,460  
Revaluation of derivative 869     –  
       
At 30 June 2026 3,288     15,774  
       

7)   Share capital

  Unaudited
Six months ended 30 June 2026
  Unaudited
Six months ended 30 June 2025
  Audited
Year ended 31 December 2025
  £000   £000   £000
Allotted, called up and fully paid:          
– 471,626,143 (H1 2025: 393,690,542, 2025: 440,415,495 ordinary shares of 10p each 47,163   39,369   44,042
– 19,327,344 deferred shares of 0.4p each 77   77   77
           
  47,240   39,446   44,119
           

During the period, the following ordinary share issues occurred:

  • On 7 April 2026, 15,873,016 ordinary shares of 10p each were allotted and issued at 63p per share pursuant to a placing and subscription.
  • On 6 May 2026, 580,791 ordinary shares of 10p each were allotted and issued following the exercise of options held by Bach Biosciences LLP.
  • On 18 May 2026, 1,604,063 ordinary shares of 10p each were issued on conversion of a portion of the unsecured convertible bond.
  • On 2 June 2026, 793,651 ordinary shares of 10p each were allotted and issued at 63p per share pursuant to a subscription.
  • On 11 June 2026, 12,792,859 ordinary shares of 10p each were allotted and issued at 70p per share pursuant to a placing.
  • On 11 June 2026, 64,284 ordinary shares of 10p each were allotted and issued at 70p per share pursuant to subscriptions.

Additionally, during the period a total of 375,000 ordinary shares of 10p each were allotted and issued following the exercise of vested employee share options. Options were exercised at prices ranging from 10p to 25p per share.

The April and June 2026 placings, together with the associated subscriptions, raised gross proceeds of approximately £18.95 million before expenses.

8)   Operating cash outflow from operations

  Unaudited     Unaudited     Audited  
  6 months ended
30 June 2026
    6 months ended
30 June 2025
    Year ended
31 December
2025
 
  £000     £000     £000  
                 
Cash flow from operating activities          
Loss for the period (19,023 )   (17,017 )   (38,612 )
Adjustments for:          
Loss from discontinued operations –     889     2,112  
Amortization 5     10     11  
Impairment losses –     –     –  
Depreciation 557     728     1,268  
Net (gain) / loss on disposal
of property, plant and equipment
(54 )   –     284  
Net (gain) / loss on disposal of Subsidiary –     705     236  
Share of loss of associate 259     189     454  
Equity-settled share-based payment charges 536     740     2,126  
Loss / (gain) on fair value of convertible bond 869     (1,009 )   1,506  
Increase in investment in associate (56 )   (56 )   (113 )
Net finance costs 4,067     3,754     6,782  
Taxation (750 )   (737 )   (1,635 )
Operating cash outflow before changes in working capital (13,590 )   (11,804 )   (26,997 )
           
(Increase) / decrease in trade and other receivables (173 )   (1,250 )   (1,020 )
Increase / (decrease) in trade and other payables (1,926 )   723     3,090  
Operating cash outflow from operations (15,689 )   (12,331 )   (24,927 )


9)  Events after the reporting period

In July 2026 the Company received an accelerated payment notice from the convertible bond holder in respect of the January 2026 quarterly deferred convertible bond repayment, as referenced most recently in the financing announced on 5 June 2026, which the Company has elected to settle in cash. Accordingly, the Company has settled the accelerated quarterly amortization payment of £3.67 million representing principal of £2.4 million together with the associated interest and fees payable in the deferment.

In September 2026 the Company received an accelerated payment notice from the convertible bond holder in respect of the April 2026 quarterly deferred convertible bond repayment, which the Company has elected to settle in cash. Accordingly, the Company has settled the accelerated quarterly amortization payment of £2.613 million, representing principal of £2.4 million together with the associated interest and fees payable in the deferment. Following the cash settlement of the April 2026 quarterly deferred convertible bond repayment, both deferred payments have now been satisfied.

As announced on 1 September 2026, the Board of Directors granted share options under the Company’s Equity Share Option Scheme incentive plan (“ESOS”) to all members of the Management Team (the “Options”). The Options are exercisable at an exercise price of 69 pence per share, being the mid-market closing price of the Company’s Ordinary Shares on 27 August 2026, the last trading date before the Options were granted.

As announced on 14 September 2026, Mats Blom, an experienced biotechnology finance executive and Board member with a strong track record as Chief Financial Officer in several life sciences companies, was appointed as a member of its Board of Directors and Chair of the Audit Committee. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Alabama hub serves more than 1,200 payroll, HR, benefits customers as Asure expands its focus on employers with 10 to 100 employees

AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) — Asure Software, Inc. (Nasdaq: ASUR), a provider of payroll and HR solutions for employers and enterprise payroll tax and treasury infrastructure, will sponsor The University of Alabama’s 72nd Annual Human Resources Management Conference on October 21–22 in Tuscaloosa and the following day will host an open house at its Gardendale, Alabama, hub office on October 23. Together, the events mark Asure’s commitment to accelerate investment in serving the fast-growing base of Alabama employers.

Asure’s Alabama hub serves more than 1,200 of the company’s direct customers. That existing customer base, combined with what Asure sees as strong growth among Alabama businesses with 10 to 100 employees, has shaped its decision to expand the hub’s role. The company is particularly keen on the tech-fueled Huntsville market, which is growing over 250% faster than the state’s overall labor force. Statewide, Alabama employers face increasing demands across payroll, HR, benefits, time and attendance, and compliance.

“More than 1,200 direct customers already rely on our local Alabama team. That gives us a strong foundation for serving more employers across the state,” said Pat Goepel, Chairman and CEO of Asure. “We see an opportunity to uniquely help Alabama’s businesses growing from 10 employees to 100: they want state of the art payroll and HR support, and value local expert support. Investing in Gardendale brings those capabilities close to home.”

Hosted by The University of Alabama at the Bryant Conference Center, the annual human resources management conference brings together HR professionals, business owners and managers for sessions on workforce management, compensation, employee development and employment law. Asure’s sponsorship connects the company with the professionals advising Alabama employers as their workforce needs evolve.

The October 23 open house 12:30pm to 4pm will bring customers, prospective customers and local business leaders together at Asure’s Gardendale hub at 2447 Decatur Highway, Gardendale. Over celebrated barbeque from Bessemer’s famous Bob Sykes BBQ, Asure plans to introduce attendees to the team serving its Alabama customers and discuss how its payroll and HR solutions help employers manage the operational work that accompanies growth. The event follows the two-day Tuscaloosa conference and extends Asure’s engagement with employers beyond the conference floor.

“The conference is an opportunity to listen to Alabama employers and their HR, compensation, and benefits leaders, and the open house is an opportunity to show them the team behind our service,” Goepel added. “Our investment in Gardendale reflects the scale of the business we already support here and our confidence in the state’s employers.”

For conference information, visit https://training.ua.edu/hrm/. For invitations and to RSVP to the October 23 open house 12:30pm-4pm at 2447 Decatur Highway, visit https://offers.asuresoftware.com/asure-bbq-open-house.

About Asure Software

Asure (Nasdaq: ASUR) provides payroll and HR solutions for employers and enterprise payroll tax and treasury infrastructure for large organizations. For employers, Asure’s platform covers payroll, HR, recruiting, time and attendance, benefits, and compliance — delivered through AsureCentral, its connected platform, or through AsureWorks, its managed services offering for employers who prefer to outsource the work entirely. For large enterprises, Asure’s payroll tax and treasury infrastructure handles multi-jurisdiction tax filing, funding, and money movement, integrating with platforms including Workday, Oracle, and SAP. For more information, visit www.asuresoftware.com.

Investor Relations Contact

Patrick McKillop
Vice President, Investor Relations
Asure Software
617-335-5058
patrick.mckillop@asuresoftware.com

  •      Rocket Doctor AI Inc. CEO, Dr. Essam Hamza to present live on October 7, 2026.
  •      Presentation will highlight Rocket Doctor AI’s growth story, recent milestones, and strategy.

Vancouver, BC, Sept. 30, 2026 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI” or the “Company”), a physician-built, AI-powered healthcare technology company focused on empowering doctors and expanding access to high-quality care, is pleased to announce that it will be presenting on October 7, 2026 at National Investment Banking Association (NIBA)’’s 153rd Investment Conference in Fort Lauderdale, Florida. CEO of Rocket Doctor AI Inc., Dr. Essam Hamza, will present a high-level overview of the company’s highlights, platform, recent milestones, and growth strategy.

Dr. Essam Hamza, CEO of Rocket Doctor AI, commented, “I am thrilled to present at NIBA’s 153rd Investment Conference in Fort Lauderdale. This event offers a fantastic opportunity to overview Rocket Doctor AI’s growth story and strategy, as well as connecting with market leading investment professionals, financing partners, and market makers.”

About National Investment Banking Association

The National Investment Banking Association (NIBA) is a non-profit organization that has been serving the micro-cap and small-cap investment community for almost 50 years. NIBA’s 153rd Investment Conference website is available here: https://nibas-152nd-investment-conference.events.accessnewswire.com/

About Rocket Doctor AI Inc.

Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.

Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 800,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices – improving efficiency, restoring autonomy to MDs, and expanding patient access to care.

By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare – making it more scalable, equitable, and patient-centered.

To learn more about Rocket Doctor AI Inc’s products and services, contact: www.rocketdoctor.ai or email: info@rocketdoctor.ai

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO, Rocket Doctor AI essam.hamza@rocketdoctor.ai

Dr. Bill Cherniak, CEO, Rocket Doctor Inc. bill@rocketdoctor.io

For media inquiries, contact: media@rocketdoctor.ai

Call: +1 (778) 819 8321

Cautionary Statements


This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Company’s participation at the National Investment Banking Association (NIBA) 153rd Investment Conference  Conference, the Company’s platform, solutions, milestones, growth strategy, and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.’s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

– Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer –

– Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies –

– The feasibility of administering more frequent repeated VCN-01 doses to potentially improve clinical outcomes in metastatic pancreatic cancer patients is currently being evaluated in the VIRAGE2 Phase 2a clinical trial –

ROCKVILLE, Md., Sept. 30, 2026 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that detailed analysis of results from the VIRAGE Phase 2b clinical trial of VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic cancer patients were published in Nature Medicine. The article, entitled “Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomised phase 2b trial”, can be read here.

“We are proud to see the peer-reviewed results from the VIRAGE trial published in Nature Medicine and made available to the entire scientific community,” said Manel Cascalló, PhD, General Director of Theriva Biologics S.L. and co-author of the article. “As elaborated in the publication, improved overall survival, progression free survival, and duration of response were observed in metastatic pancreatic cancer patients treated with VCN-01 combined with standard-of-care (SoC) gemcitabine/nab-paclitaxel chemotherapy compared to patients receiving SoC chemotherapy alone. Moreover, the Kaplan-Meier survival analysis and the timing of responses in VCN-01 treated patients suggest an immune mediated mechanism of action for VCN-01 in addition to its stroma degrading effects. We are excited about the potential for VCN-01 in different cancer therapy combinations, and we are extremely grateful to the patients who participated in VIRAGE, their families, our clinical investigators and their teams, and our co-authors for their commitment, dedication and diligence.”

As previously reported, greater improvements in patient survival during the VIRAGE study were observed in metastatic pancreatic cancer patients receiving 2 doses of VCN-01 administered 3 months apart, Following End-of-Phase 2 feedback from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), Theriva has recently initiated VIRAGE2; a small Phase 2a study designed to evaluate the feasibility of more frequent, repeated dosing of VCN-01 in combination with SoC chemotherapy. The first patient in VIRAGE2 was treated in August 2026, and the study is expected to complete enrollment during the second half of 2026. Initial pharmacodynamic and safety/tolerability data are anticipated by Q3 2027. Results from VIRAGE2 will inform the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial. For more details see About VIRAGE2 below.

In parallel with VIRAGE2, Theriva is engaging with the FDA to finalize the design of a potential Phase 2/3 study evaluating VCN-01 in children with retinoblastoma with vitreous seeds that are refractory/resistant to the use of current intravitreal chemotherapy. VCN-01 has received Rare Pediatric Disease designation for the treatment of retinoblastoma and may be eligible to receive a Priority Review Voucher if VCN-01 is approved in this indication by September 30, 2029.

About Pancreatic Ductal Adenocarcinoma

Cancer of the pancreas consists of two main histological types: cancer that arises from the ductal (exocrine) cells of the pancreas or, much less often, cancers may arise from the endocrine compartment of the pancreas. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic tumors. It can be located either in the head of the pancreas or in the body/tail. Pancreatic cancer usually metastasizes to the liver and peritoneum. Other less common metastatic sites are the lungs, brain, kidney, and bone. In its early stages, pancreatic cancer does not typically result in any characteristic symptoms. In many instances, progressive abdominal pain is the first symptom. Therefore, in most cases, pancreatic cancer is diagnosed in its late stages (locally advanced non-metastatic or metastatic stage of the disease) when surgical resection and possibly curative treatment is not possible. It is generally assumed that only 10% of cases are resectable at presentation, whereas 30-40% of patients are diagnosed at local advanced/unresectable stage and 50-60% present with distant metastases.

About VCN-01

VCN-01 (zabilugene almadenorepvec) is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action is intended to enable VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to 142 patients to date in Company- and investigator-sponsored clinical trials in different cancers, including PDAC (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection). VCN-01 has also been made available for compassionate use in retinoblastoma patients, and 2 patients have been treated in this program. VCN-01 has been granted Orphan Drug designation for the treatment of metastatic PDAC and retinoblastoma in Europe and the USA, as well as FDA Fast Track designation for the treatment of metastatic PDAC and Rare Pediatric Disease designation for the treatment of retinoblastoma. More information on VCN-01 clinical trials is available at Clinicaltrials.gov.

About VIRAGE

VIRAGE (EUCT 2024-511290-30-00; NCT05673811) was a two-arm, Phase 2b open-label, randomized, controlled, multicenter clinical trial in patients with histologically confirmed, newly-diagnosed metastatic PDAC. A total of 112 patients were enrolled at 5 sites in the U.S. and 9 sites in Spain. In both the control and VCN-01 (zabilugene almadenorepvec) treatment arms, patients received gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy in repeated 28-day cycles until disease progression. In the VCN-01 treatment arm only, patients were also administered intravenous VCN-01 seven-days prior to starting the first and fourth cycles of gemcitabine/nab-paclitaxel treatment (study days 1 and ~92 respectively). As previously reported and presented, PDAC patients in the VCN-01 plus gemcitabine/nab-paclitaxel SoC treatment arm demonstrated increased overall survival, progression free survival, and duration of response compared to patients in the control arm treated with gemcitabine/nab-paclitaxel SoC alone. Greater improvements in these parameters were observed in patients who received 2 doses of VCN-01 administered 3 months apart, and the pharmacokinetics of VCN-01 were not different between the 2 doses despite the presence of neutralizing antibodies.

About VIRAGE2

VIRAGE2 (EUCT: 2026-525566-21-00; NCT07701486) is a Phase 2a, single-arm, open-label, clinical trial in 6 evaluable patients with histologically confirmed, newly diagnosed metastatic PDAC enrolled at a single site in Spain. Patients are intended to receive at least three “macrocycles” of VCN-01 (zabilugene almadenorepvec) and gemcitabine/nab-paclitaxel SoC chemotherapy, followed by SoC gemcitabine/nab-paclitaxel cycles until disease progression. In each VCN-01 macrocycle, intravenous VCN-01 is administered on day 1 followed by gemcitabine/nab-paclitaxel SoC chemotherapy on days 8, 15, 22, 36, 43, and 50. Macrocycles are repeated on days 57 and 113. The primary objective of the VIRAGE2 trial is to evaluate whether administration of at least 3 doses of VCN-01, with 2 months between doses, is well tolerated by patients without adversely impacting VCN-01 pharmacodynamics. Primary endpoints for the trial are the adverse event profile and levels of VCN-01 viral genomes in blood. Secondary endpoints include objective response rate, duration of response, progression free survival, overall survival, and circulating levels of anti-VCN-01 neutralizing antibodies. Exploratory endpoints include estimates of potential VCN-01 shedding by measuring VCN-01 viral genomes in sputum and stool. The study is not formally powered for evaluation of clinical efficacy endpoints and is intended to support evaluation of the potential efficacy of the more frequent repeated dosing regimen in subsequent clinical trials.

About Theriva™ Biologics, Inc.

Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidate is VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. An exploratory clinical trial remains open with SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Enrollment is paused and completion of this trial is pending receipt of grant funding or funding through a partnership or other collaboration. For more information, please visit Theriva™ Biologics’ website at www.therivabio.com.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding publication in Nature Medicine validating the VIRAGE study and supporting the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer; more frequent, repeated VCN-01 potentially improving clinical outcomes in metastatic pancreatic cancer patients; the potential for VCN-01 in different cancer therapy combinations, the VIRAGE2 study expecting to complete enrollment during the second half of 2026; initial pharmacodynamic and safety/tolerability data from VIRAGE2 being anticipated by Q3 2027; results from the VIRAGE2 study informing the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial; administering at least 3 doses of VCN-01 in the VIRAGE2 trial given approximately 2 months apart in combination with standard-of-care chemotherapy; finalizing with the FDA the design of a potential Phase 2/3 study evaluating VCN-01 in children with retinoblastoma with vitreous seeds that are refractory/resistant to the use of current intravitreal chemotherapy; and receiving a Priority Review Voucher if VCN-01 is approved for the treatment of retinoblastoma by September 30, 2029. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to finalize protocols for future clinical trials evaluating VCN-01; results of future trials supporting further clinical development of VCN-01 and supporting the benefits of more frequent repeated dosing of VCN-01; the Company’s ability to obtain development funding and/or partnerships; the Company’s commencement of planned clinical trials, which remains subject to sufficient financing; the Company’s ability to raise capital and/or enter into one or more strategic alternatives, that may include a business combination, merger or reverse merger; the Company’s ability to reach clinical milestones when anticipated, including the ability to continue to enroll patients as planned; generating clinical data that establishes VCN-01 may improve patient outcomes in cancer patients; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, including approval of VCN-01 to treat cancer patients; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for the specific indications; acceptance of the Company’s product candidates in the marketplace; the successful development, marketing or sale of the Company’s products; developments by competitors that render such products obsolete or non-competitive; the Company’s ability to maintain license agreements; the continued maintenance and growth of the Company’s patent estate; the ability to continue to remain well financed; and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

For further information, please contact:
Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com

Source: Theriva Biologics, Inc.

Starcloud’s SC-1L compute payload to operate onboard Firefly’s Elytra spacecraft in lunar orbit, validating capabilities for a future orbital lunar data center

Firefly Elytra - Starcloud Payload

*Rendering of Firefly’s Elytra vehicle in lunar orbit with Starcloud’s compute payload onboard

CEDAR PARK, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) — Firefly Aerospace (Nasdaq: FLY), a market leading space and defense technology company, today announced a new commercial payload agreement with Starcloud to demonstrate advanced AI computing capabilities in lunar orbit. Starcloud’s computing payload, designated SC-1L, will fly onboard Firefly’s Elytra orbital vehicle to validate the core capabilities of a future data center around the Moon that can support lunar surface and orbital infrastructure.

“We’re proud to collaborate with innovative customers like Starcloud and collectively take another step toward establishing the infrastructure that will power a permanent human and robotic presence at the Moon,” said Ray Allensworth, Vice President of Spacecraft at Firefly Aerospace. “By pairing Starcloud’s AI computing payload with our Elytra vehicle and Solux vision system, we’re demonstrating how data can be captured, processed, and delivered from lunar orbit, laying the groundwork for the computing infrastructure future lunar operations will depend on.”

Integrated on Elytra, Starcloud’s SC-1L processor will ingest data from Firefly’s onboard Solux vision system, perform high-power AI computing on orbit, and rapidly transmit the processed data back to Earth. The demonstration builds directly on Starcloud’s recent AI computing demonstration in low Earth orbit, extending those proven capabilities into lunar orbit.

Starcloud is being onboarded to Firefly’s third lunar mission that’s targeted to launch no earlier than 2028. For this mission, Firefly’s Elytra orbiter will first serve as the transfer vehicle and communications relay for Firefly’s Blue Ghost lander that will land on the Moon’s Gruithuisen Domes and operate several science and technology instruments as part of NASA’s Commercial Lunar Payload Services (CLPS) initiative. Following completion of the mission, Elytra will remain in lunar orbit for five years to enable customer payload and imaging operations, including Starcloud’s demonstration.

“Space is the future of data centers, and the Moon is the next frontier for that vision,” said Ezra Feilden, Cofounder and CTO at Starcloud. “We successfully validated our ability to run and train AI models on enterprise grade GPUs in low Earth orbit, and now we’re taking this proven technology to lunar orbit. Onboard Firefly’s Elytra vehicle, we’ll demonstrate high-power AI computing and further prove we can process massive volumes of data right where it’s generated to support the growing infrastructure beyond Earth.”

Formerly known as Sol3, Firefly’s Solux vision system onboard Elytra enables spacecraft to autonomously navigate, land, and track their orientation in space environments where Global Navigation Satellite Systems (GNSS) and GPS are unavailable. Elytra will also have high-resolution telescopes onboard to enable Firefly’s Ocula lunar imaging service that provides advanced lunar surface mapping, mineral detection, and reconnaissance.

This will be the second Elytra vehicle Firefly is deploying to lunar orbit following the launch of Blue Ghost Mission 2, targeted for no earlier than 2027. Each Elytra vehicle is designed to remain in lunar orbit for up to five years, enabling more rapid revisit times of the lunar surface for government and commercial customers.

Firefly also recently announced a collaboration with NVIDIA to process data on orbit for its Ocula lunar imaging service. The Ocula data will be rapidly processed onboard Elytra in lunar orbit and autonomously transmitted back to Earth utilizing the NVIDIA Jetson module and Firefly’s AI software through its SciTec subsidiary. This allows Firefly to mitigate downlink constraints from the Moon by processing data in lunar orbit before it is transmitted to Earth as real-time, actionable insights.

About Firefly Aerospace
Firefly Aerospace is a space and defense technology company on a mission to reliably and repeatedly launch, land, and operate space systems from Earth to the Moon and beyond. As the partner of choice for responsive space missions, Firefly is the first commercial company to launch a satellite to orbit with approximately 24-hour notice and the first to achieve a successful landing on the Moon. Established in 2017, Firefly’s engineering, manufacturing, and test facilities are co-located in central Texas to enable rapid innovation and vertical integration for the company’s small- to medium-lift launch vehicles, lunar landers, and orbital vehicles. For more information, visit www.fireflyspace.com.

Forward-Looking Statement
This press release contains “forward-looking statements” including, but not limited to, statements regarding the expected capabilities and demonstrations of Elytra, Solux and Ocula lunar imaging service, expected launch dates for Blue Ghost missions, AI capabilities, statements of Firefly’s Vice President of Spacecraft, and other statements regarding Firefly’s future expectations, beliefs, plans, objectives, financial condition, assumptions, future events, or performance that are not historical facts. In some cases, you can identify forward-looking statements because they contain words such as “allows” “enable,” “may,” “position,” “will,” “expects,” “plans,” “anticipates,” “could,” “would,” “target”, “set,” “intends,” “support,” and “believes.” There may also be negative words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Not all forward-looking statements contain such identifying words. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates, or expectations will be achieved.

Various risks that could cause actual results to differ from those expressed by the forward-looking statements included in this press release include, but are not limited to: our failure to manage our growth effectively, including the increasing technological complexity of our business, and our ability to achieve and maintain profitability; the potential for delayed or failed launches, and any failure of our launch vehicles and spacecraft to operate as intended; our inability to deliver software on time or of a quality that our customers demand; the hazards and operational risks that our products and service offerings are exposed to, including the wide and unique range of risks due to the unpredictability of space; the inability to realize our backlog; the fluctuation of our operating results; adverse publicity stemming from any incident involving us, our competitors, or our customers; the failure to adequately protect our proprietary intellectual property rights; our inability to comply with our contractual obligations; and other risk factors set forth in our filings with the Securities and Exchange Commission. 

Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. These statements are based on management’s current expectations, assumptions, and beliefs concerning future developments, which are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. We cannot assure you that the events reflected in the forward-looking statements will occur; actual events could differ materially from those described in the forward-looking statements. We undertake no intent or obligation to publicly update or revise any of the estimates and other forward-looking statements made in this announcement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact
press@fireflyspace.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3111ca86-936c-41ba-9720-bd90184f89e6

– Loop Diuretic Route of Administration Option Is Delivered As A Single-Use Nasal Spray –

– Nasal Route Offers a Direct Path to Systemic Absorption Without Relying on the GI Tract –

ANN ARBOR, Mich., Sept. 30, 2026 (GLOBE NEWSWIRE) — With more than six million Americans living with heart failure and healthcare systems increasingly focused on delivering care beyond traditional care settings, Esperion, a company wholly-owned by ARCHIMED, is launching a nationwide effort to raise awareness of ENBUMYST™ (bumetanide nasal spray), a short-term nasal diuretic indicated for the treatment of edema associated with congestive heart failure. As the healthcare landscape prepares for the implementation of the Centers for Medicare & Medicaid Services’ Ambulatory Specialty Model (ASM) in 2027, Esperion aims to educate clinicians, patients, and caregivers about available treatment options and the role novel routes of administration have in heart failure care.

“The implementation of the Ambulatory Specialty Model in 2027 reflects a broader transformation in how heart failure care is delivered and managed,” said Bill Fairey, Interim President and CEO, Esperion. “We believe innovation extends beyond molecules to include how therapies are delivered. Through our acquisition of ENBUMYST, we have expanded Esperion’s portfolio with a novel intranasal route of administration, and we are committed to helping stakeholders understand the full spectrum of treatment options available for patients living with heart failure.”

“For many patients living with heart failure, worsening edema can quickly lead to an emergency department visit for IV therapy. The availability of intranasal bumetanide provides clinicians another treatment option for appropriate patients outside of traditional IV-dependent care settings,” said Andrew P. Ambrosy, MD, MPH, cardiologist and clinician-investigator at Kaiser Permanente Northern California Division of Research and lead author of the ENBUMYST bioequivalence study. “Having a short-term, at-home intranasal treatment option available offers clinicians greater flexibility in how diuretic therapy can be delivered.”

To help patients, caregivers, clinicians, and healthcare stakeholders navigate an evolving heart failure care landscape, Esperion is advancing several education and awareness initiatives, including:

  • Strategic targeting of integrated delivery networks navigating the new ASM model effective in January 2027.
  • Focused educational materials for HCPs, including nurse practitioners and physician assistants, as well as patients with heart failure and their caregivers.
  • Presence at several HF-focused medical meetings during the second half of 2026 and into 2027.
  • Partnerships with several leading patient and professional organizations, such as the Heart Failure Society of America, supporting medical professionals and heart failure patients.
  • Initiation of robust data generation activities to support the use of ENBUMYST in heart failure treatment.

The Ambulatory Specialty Model (ASM) for heart failure is a mandatory Centers for Medicare & Medicaid Services (CMS) value-based payment model scheduled to launch on January 1, 2027, and continue through December 31, 2031. The model is designed to hold participating specialty providers accountable for the cost and quality of care delivered to Medicare beneficiaries with heart failure across selected geographic regions.

What is ENBUMYST?

ENBUMYST is a prescription medicine used in adults to treat swelling caused by excess fluid in the body (edema) from congestive heart failure, liver disease, and kidney disease.

What is the most important information I should know about ENBUMYST?

  • ENBUMYST is a diuretic that helps your body remove fluid. Losing too much fluid can cause dehydration, low blood volume, and increase the risk of blood clots. Blood abnormalities may include decreased salts (electrolytes), and increased nitrogen, glucose and uric acid. The risk of these abnormalities is higher in elderly people, those using higher doses, or those who do not get enough electrolytes by mouth.
  • You should not use ENBUMYST if you have severe electrolyte loss.
    Tell your healthcare provider if you experience unusual thirst; dizziness or lightheadedness; weakness or tiredness; fast heart rate; dry mouth or tongue; sudden pain; redness or swelling in your joints; pain, swelling, redness, or warmth in your leg; shortness of breath or fast breathing; high blood sugar; dark urine; pale, tight, cool or clammy skin; muscle cramps; confusion.

Do not use ENBUMYST if you have low or no urine production or are allergic to bumetanide or to any of the ingredients in ENBUMYST.

Before using ENBUMYST, tell your healthcare provider if you have low electrolytes, are on a low-salt diet, have diarrhea, diabetes, nasal problems such as a runny or stuffy nose or polyps, a history of nasal injury or surgery, are or plan to become pregnant, are or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescriptions, over-the-counter medicines, vitamins, and herbal supplements.

ENBUMYST may cause serious side effects, such as worsening kidney function and ringing in the ears or hearing loss.

The most common side effects of ENBUMYST include dehydration, headache, muscle cramps, dizziness, low blood pressure, nausea, and abnormal brain functioning with certain liver problems.

These are not all the possible side effects of ENBUMYST. Talk to your healthcare provider for more information.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

About Esperion
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Services, and MedTech. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation. For more information about ARCHIMED, please visit www. ARCHIMED.group.

Esperion Contact Information: 
Tiffany Aldrich  
corporateteam@esperion.com  
(616) 443-8438 

NUC-7738 is protected by over 85 issued patents worldwide

EDINBURGH, United Kingdom, Sept. 30, 2026 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the European Patent Office (“EPO”) has granted an important patent covering the composition of matter for NUC-7738.

This patent (EP 3683225) is a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition-of-matter patent covers the chemical structure of NUC-7738, NuCana’s novel anti-cancer agent currently being evaluated in the Phase 2 part of a Phase 1/2 clinical study (NuTide:701) in combination with Keytruda® (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma.

Securing this patent represents an important milestone for NuCana, further strengthening the Company’s long-term global intellectual property strategy and the potential commercial protection of NUC-7738.

Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer, said: “We are delighted that the EPO has granted this important new patent, which further strengthens the intellectual property protection of NUC-7738 and reflects the strength and novelty of our science. This composition-of-matter patent is a critical addition to our global patent estate for NUC-7738, which now spans over 85 issued patents worldwide, and builds upon similar composition-of-matter patents previously granted in both the United States and China. This underscores our commitment to protecting NUC-7738’s long-term commercial potential across all major markets. With cash resources expected to fund our planned operations into 2029, we believe we are well positioned to advance the clinical development of NUC-7738 and to deliver on a number of important milestones over the remainder of 2026 as we work to bring meaningful new treatment options to patients with cancer.”

About NuCana

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a targeted thymidylate synthase (“TS”) inhibitor designed to overcome key pharmacological limitations associated with other TS inhibitors. NUC-3373 has recently been evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer, and NuCana is currently evaluating further characterization of mode of action and target indications for further clinical studies of NUC-3373.

Forward-Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of the Company. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-7738 and NUC-3373; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company’s current cash and cash equivalents to fund its planned operations into 2029. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to raise additional capital sufficient to fund our planned operations and the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the Securities and Exchange Commission (“SEC”) on March 19, 2026, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

NuCana plc
Hugh S. Griffith
Chief Executive Officer
+44 131-357-1111
info@nucana.com

ICR Healthcare
Chris Brinzey
+1 339-970-2843
Chris.Brinzey@ICRHealthcare.com

CTS Introduces Its First Digital Temperature Sensor Platform, Expanding Smart Sensing Capabilities

Built around a high-accuracy digital sensing architecture, CTS Digital Temperature Sensors are designed to deliver reliable temperature measurement and digital communication capabilities for applications requiring precise monitoring and system-level intelligence
Built around a high-accuracy digital sensing architecture, CTS Digital Temperature Sensors are designed to deliver reliable temperature measurement and digital communication capabilities for applications requiring precise monitoring and system-level intelligence

LISLE, Ill., Sept. 30, 2026 (GLOBE NEWSWIRE) — CTS Corporation (NYSE: CTS), a leading designer and manufacturer of sensors, connectivity components, and actuators, today announced the introduction of its first Digital Temperature Sensor platform, expanding the company’s temperature sensing portfolio with high-accuracy digital sensing solutions designed to support a broad range of industrial, medical, transportation, and electronics applications.

This introduction marks a significant expansion of CTS’s temperature sensing capabilities, complementing the company’s established portfolio of temperature sensing technologies with digital communication functionality that enables simplified integration into modern connected systems.

Built around a high-accuracy digital sensing architecture, CTS Digital Temperature Sensors are designed to deliver reliable temperature measurement and digital communication capabilities for applications requiring precise monitoring and system-level intelligence. The platform supports a variety of probe styles and configurations, enabling engineers to select solutions that best fit their performance and installation requirements.

“With the introduction of our Digital Temperature Sensor platform, CTS is broadening its temperature sensing portfolio to better serve both existing and future customers,” said Shahela Ali, Product Manager at CTS Corporation.

CTS Digital Temperature Sensors are designed for applications requiring accurate temperature monitoring, digital communication, and flexible packaging options. By adding digital sensing technology to its portfolio, CTS further strengthens its ability to support customers throughout the product development lifecycle, from initial design through production.

Key benefits include:

  • High-accuracy digital temperature measurement
  • Digital communications designed for simplified system integration
  • Multiple probe and housing configurations
  • Traceable temperature measurement capability
  • CTS engineering and application support

The Digital Temperature Sensor platform is available in multiple configurations to support a wide range of application requirements.

For more information about CTS Digital Temperature Sensors, visit: Digital Temperature Sensor

About CTS

CTS (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect, and Move. The company manufactures sensors, actuators, and electronic components in North America, Europe, and Asia, serving customers in the aerospace/defense, industrial, medical, and transportation markets. For more information, visit www.ctscorp.com.

Media Relations Contact
Amela Smajlovic
Marketing Director

CTS Corporation
4925 Indiana Avenue
Lisle, IL 60532

E-mail: amela.smajlovic@ctscorp.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/717930a6-3832-4992-a369-79fb8d45dabf

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work

AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026

AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined development path

ALISO VIEJO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced receipt of the official minutes from its Biosimilar Biological Product Development (“BPD”) Type 2b meeting held with the U.S. Food and Drug Administration (“FDA” or the “Agency”) regarding ABP-450’s development pathway.

“The Type 2b meeting feedback provides greater clarity on the development pathway for ABP-450 and, consistent with FDA’s recent biosimilar guidance, supports a potentially more efficient clinical development program,” said Rob Bancroft, President and Chief Executive Officer of AEON. “Our strategy is to bring together the most sensitive, complementary and relevant evidence available, including our analytical program, comparative human pharmacodynamic data and the substantial comparative human experience already generated with ABP-450. Where those lines of evidence converge, we believe they may support proceeding without a standalone comparative efficacy study or narrowing the clinical work required, improving the capital and time efficiency with which we advance ABP-450 toward its potential commercial opportunity. We are excited to embark on this next phase of ABP-450’s development and look forward to submitting the IND for the CMAP study later this year.”

The Type 2b meeting provided feedback across the following components of AEON’s development plan:

Comparative Pharmacodynamic Study

AEON proposed a two-stage design for a comparative pharmacodynamic (“PD”) study using Compound Muscle Action Potential (“CMAP”) measurement in the extensor digitorum brevis muscle consisting of an initial dose-finding stage followed by a comparative PD evaluation. The FDA agreed in principle with the initial dose-finding stage which will be conducted in healthy volunteers. The FDA also provided recommendations intended to strengthen the study’s ability to demonstrate assay sensitivity. AEON intends to incorporate the FDA’s feedback and advance the study under an investigational new drug application (“IND”), which the Company expects to submit in the fourth quarter of 2026.

In a biosimilar development program, PD measures are tests that evaluate the biological, molecular, and physiological effects a drug has on the body to confirm that the biosimilar interacts with its intended therapeutic target in a similar way as the original reference biologic. PD evidence is particularly important for a botulinum toxin, which acts locally and is not present at reliably measurable systemic concentrations following therapeutic administration, making conventional comparative pharmacokinetic studies infeasible.

Previously Completed Comparative Studies

The FDA indicated that comparative clinical studies previously conducted by Daewoong Pharmaceutical across several indications including studies in blepharospasm, upper limb spasticity, glabellar lines and lateral canthal lines, can be submitted for consideration as supportive evidence, subject to appropriate scientific bridging to U.S.-licensed BOTOX® and between the ABP-450 drug product used in each study and ABP-450 as currently manufactured. Blepharospasm and upper limb spasticity are therapeutic indications included on the U.S. BOTOX® label, while glabellar lines and lateral canthal lines are included on the BOTOX Cosmetic® label.

These studies evaluated ABP-450 relative to BOTOX® across a range of indications, doses and muscles, with each study meeting its pre-specified non-inferiority endpoint. AEON intends to complete the scientific bridging work necessary to support their consideration within the totality of evidence for ABP-450. If appropriately bridged, AEON believes these studies could complement the analytical and PD programs by providing additional comparative human evidence supportive of biosimilarity.

Comparative Clinical Study Considerations

The FDA’s scientific approach to biosimilar development has continued to evolve toward greater reliance on evidence that is most sensitive to detecting meaningful differences between a proposed biosimilar and its reference product. In October 2025, the FDA issued draft guidance recognizing that traditional comparative efficacy studies (“CES”) generally have limited sensitivity to detect product differences and may not be necessary where more sensitive evidence sufficiently supports a determination of biosimilarity. The guidance reflects the FDA’s growing experience that traditional clinical efficacy endpoints may provide limited additional discriminatory information in biosimilar development.

Consistent with this evolving framework, during the Type 2b meeting, the FDA emphasized that, if additional clinical evidence is ultimately needed, such evidence should be sufficiently sensitive to detect a meaningful difference between the products, if one exists. The FDA also indicated that more sensitive measures of biological activity, rather than traditional clinical efficacy endpoints, could be considered and that the design of any additional clinical study should be guided by the specific residual uncertainty remaining following completion of the comparative analytical assessment (“CAA”). Accordingly, AEON does not intend to initiate a CES at this time and will first evaluate the totality of its analytical, pharmacodynamic and comparative human evidence to determine whether additional clinical evidence is scientifically necessary and, if so, the most appropriate approach to address any remaining residual uncertainty.

Indication-Specific Considerations

The FDA feedback also addressed indication-specific considerations, including chronic migraine. During the meeting, the FDA invited the Company to provide analyses supporting the rationale for the outcome of the previously conducted Phase 2 study for the prevention of migraine headache, which the Company intends to complete and provide to the FDA as part of its 351(k) Biologics License Application (“BLA”) submission.

Comparative Analytical Assessment

The CAA is the scientific foundation of development under the 351(k) pathway and provides a sensitive means of identifying potential structural and functional differences between a proposed biosimilar and its reference product. AEON is conducting a broad CAA of ABP-450 and U.S.-licensed BOTOX® across structural, physicochemical and functional attributes. The Company recently reported progress across multiple dimensions of that program, including expanded primary-sequence characterization, confirmation of critical disulfide-bond architecture, and pilot forced-degradation results demonstrating highly similar degradation behavior between ABP-450 and BOTOX® under thermal and oxidative stress conditions. 

Next Steps: Converging Evidence

AEON’s next phase of development will integrate its maturing comparative analytical foundation with multiple independent and complementary lines of evidence, including human PD evidence, existing comparative human evidence scientifically bridged to the biosimilar program, and targeted evidence addressing indication-specific questions. The Company intends to leverage the convergence of these evidence streams to build a scientifically supported case whereby a standalone CES may not further inform a determination of biosimilarity. AEON plans to return to the FDA in 2027 with its integrated evidence package.

Anticipated milestones for ABP-450’s development program include:

  • Continued completion of CAA studies in support of biosimilarity between ABP-450 and BOTOX® 
  • Filing an IND for CMAP PD study in Q4 2026
  • CMAP PD study initiation in Q1 2027
  • Scientific bridging of ABP-450 and BOTOX® to support previously completed comparative studies

About the U.S. Biosimilar Pathway

The 351(k) biosimilar pathway is grounded in a totality-of-the-evidence approach. The FDA evaluates a proposed biosimilar using the most sensitive and scientifically informative methods available to identify potential differences from its reference product, with comparative analytical assessment providing the scientific foundation. The nature and extent of any additional studies the FDA may require prior to approval are informed by the residual uncertainty remaining after that assessment. Once biosimilarity is established, the FDA has the authority to approve a biosimilar for additional indications of the reference product through scientifically justified extrapolation, without requiring separate clinical studies in each indication.

In October 2025, the FDA issued draft guidance proposing that a comparative efficacy study — a comparative clinical study with efficacy endpoints — may not be necessary where a comparative analytical assessment demonstrates that a proposed product is highly similar to its reference product. The draft guidance reflects the FDA’s view that comparative analytical methods are generally more sensitive than comparative efficacy studies for detecting differences between products.

About AEON Biopharma

AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of certain third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements generally relate to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward-looking statements in this press release include, among others, (i) statements regarding the Company’s plans and expected timing to submit an IND and initiate the CMAP pharmacodynamic study; (ii) the design, execution and potential evidentiary value of that study; (iii) the Company’s ability to complete its comparative analytical assessment and the scientific bridging necessary to support consideration of previously completed comparative studies; (iv) the potential for analytical, pharmacodynamic and existing comparative human evidence, individually or collectively, to support a determination of biosimilarity or reduce the need for a standalone comparative efficacy study; (v) the nature and scope of any additional clinical studies that may be required; (vi) the timing and outcome of future interactions with the FDA, including the Company’s planned engagement with the FDA in 2027; and (vii) the Company’s ability to advance ABP-450 through the 351(k) pathway toward potential full-label therapeutic approval and commercial entry. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “potential,” “will,” “predict” and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the Company’s forward-looking statements include, among others, (viii) the FDA’s interpretation of the data and information generated or submitted by the Company; (ix) the possibility that the FDA may require additional analytical, pharmacodynamic, clinical or other studies; (x) the Company’s ability to successfully complete its planned studies and scientific bridging activities; (xi) whether the results of those activities will support the Company’s proposed development approach; (xii) changes in FDA guidance, regulatory requirements or interpretations, including with respect to the role of comparative clinical studies in biosimilar development; (xiii) the Company’s ability to obtain sufficient capital to fund its planned development activities; (xiv) and other risks described in the Company’s filings with the Securities and Exchange Commission. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update such statements except as required by applicable law.

Contacts
Investor Contact:
Hershel Berry
Blueprint Life Science Group
hberry@bplifescience.com
Source: AEON Biopharma

Ranks #1 globally with lowest Mean Absolute Error on Visa, Application, and Mugshots datasets, strengthening its position in age assurance

Independent NIST results signal ROC’s progression from U.S. leader to global leader in facial age estimation

DENVER, CO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Rank One Computing Corporation d/b/a ROC (Nasdaq: ROC) (“ROC” or the “Company”), a U.S. leader in Vision AI, building unified biometric, video analytics, and digital evidence solutions, today announced that its latest NIST submission achieved #1 global ranking in age estimation demonstrating accuracy across three primary datasets in the National Institute of Standards and Technology (“NIST”) Face Analysis Technology Evaluation for Age Estimation and Verification (“FATE AEV”). ROC also maintained its previously recognized #1 global position in the Child Online Safety evaluation for ages 13-16.

“ROC’s latest NIST achievement moves us from U.S. leader to ranking #1 globally across three primary age estimation datasets, while maintaining our leading position in Child Online Safety,” said ROC Chief Executive Officer B. Scott Swann. “These results provide important independent validation of our technology, which we believe strengthens ROC’s competitive position to grow across government and commercial customers seeking accurate, scalable, and cost-efficient age intelligence solutions.”

These results extend ROC’s leadership in age estimation, adding Visa and Application to its #1 rankings in Mugshots and Child Online Safety. For organizations evaluating identity and biometrics technology, NIST’s third-party measures offer an important benchmark for assessing performance across different operational environments and informing technology selection and procurement decisions.

ROC Chief Scientist and Co-Founder Dr. Brendan Klare, commented, “Six months ago, ROC landed the top spot among U.S. age estimation vendors in NIST FATE testing. Today, our ROC-003 algorithm ranks #1 globally in MAE on three of NIST’s four primary datasets. This progress reflects the skill and persistence of the team behind our algorithms as we continue to push the science forward.”

“Age estimation is ready to play a bigger role in age assurance. Our goal is to give organizations a precise, low friction signal they can use to shape an experience, apply protections, or determine when additional verification is needed. ROC’s latest NIST results demonstrate the accuracy this technology can achieve and its potential to support high-impact missions like child online safety,” added ROC Chief Operating Officer Blake Moore.

ROC’s latest algorithm submission, ROC-003, achieved the lowest Mean Absolute Error (“MAE”) across the Visa, Application and Mugshots datasets for adults ages 18–30, ranking first globally on three of the four primary datasets evaluated. Importantly, the lower the MAE, the greater the accuracy to the age estimate. These results expand ROC’s previously established leadership in age estimation and demonstrate continued improvements in algorithmic accuracy to confidently guide critical identification decisions.

NIST FATE is a government-run benchmarking program for face analysis tasks beyond recognition. For age estimation, the FATE Age Estimation & Verification (AEV) track is an ongoing evaluation of software algorithms that inspect face photos and produce an age estimate. NIST publishes results on accuracy and computational efficiency, and notes that facial age verification has been mandated in legislation in a number of jurisdictions, typically to protect minors. The AEV track is open to a worldwide community of developers under a standardized submission process.

Read ROC’s Blog Post and Full NIST Scores here.

About ROC
ROC is a leading U.S. developer and manufacturer of Vision AI, delivering sovereign biometrics, video analytics, and digital evidence through a unified platform. This enables agency and integrator partners to unlock faster, more accurate, and cost-efficient capabilities. At its core, ROC transforms raw pixels into real-time operational awareness for defense, public safety, and digital commerce. The Company is headquartered in Denver, Colo., with additional hubs in Grand Rapids, Mich., and Morgantown, W.Va. For more information, please visit the Company’s website: www.roc.ai.

Forward-Looking Statements
This Press Release may contain forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” and similar statements and expressions that predict or indicate future events or trends or that are not statements of historical fact. Therefore, caution must be exercised in relying on forward-looking statements as actual results may differ materially and adversely from those expressed in any forward-looking statements. ROC may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about the parties’ beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: (i) ROC’s goals and strategies and (ii) ROC’s future business development, financial condition, and results of operations. Further information regarding these and other risks is included in ROC’s filings with the SEC. All information provided in this press release is provided, and the forward-looking statements included herein are made, solely as of the date of this press release, and neither party undertakes any obligation to revise or update any forward-looking statement, except as required under applicable law.

Media inquiries:
Matt Aitken, VP of Marketing
media@roc.ai

Investor inquiries:
CORE IR
ir@roc.ai

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.